FDA Clears Mounjaro to Cut Heart Attack, Stroke and Cardiovascular Death Risk in High‑Risk Adults With Type 2 Diabetes

Eli Lilly announced FDA approval of Mounjaro (tirzepatide) to reduce the risk of heart attack, stroke and cardiovascular death in high‑risk adults with type 2 diabetes, based on the SURPASS‑CVOT trial of 13,299...



























